Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 5/20 | 0.57 |
| ▸ | NT5E | P21589 | 12/20 | 0.56 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22214990 | 0.87 | CDK1 (0.55) | CDK1NT5ECDK5NPC1CDK2 | |
| SCHEMBL22214988 | 0.85 | NT5E (0.54) | NT5ECDK5NPC1 | |
| SCHEMBL22843642 | 0.83 | CDK1 (0.56) | CDK1NT5ECDK5KDM4ENPC1 | |
| SCHEMBL19370191 | 0.81 | NT5E (0.57) | CDK1NT5ECDK5KDM4ENPC1 | |
| SCHEMBL24835901 | 0.80 | CDK1 (0.51) | CDK1NT5ECDK5KDM4ENPC1 | |
| SCHEMBL19370192 | 0.79 | NT5E (0.58) | CDK1NT5ECDK5 | |
| SCHEMBL19370203 | 0.79 | NT5E (0.52) | CDK1NT5ECDK5 | |
| SCHEMBL24078875 | 0.79 | NT5E (0.47) | CDK1NT5ECDK5CDK2 | |
| SCHEMBL22215136 | 0.78 | NT5E (0.52) | NT5E | |
| SCHEMBL19370180 | 0.78 | NT5E (0.58) | CDK1NT5ECDK5CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11058704-B2 | Inhibitors of adenosine 5′-nucleotidase | ARCUS BIOSCIENCES, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ARCUS BIOSCIENCES, INC. | 2020-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11058704-B2 | Inhibitors of adenosine 5′-nucleotidase | ENTPD5, NT5C2, ENTPD1 | CDK1 2231/4885NT5E 4/4885CDK5 1095/4885 |
| US-20200222441-A1 | INHIBITORS OF ADENOSINE 5'-NUCLEOTIDASE | ENTPD5, NT5C2, ENTPD1 | CDK1 2246/4885NT5E 4/4885CDK5 1053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.